Raffles Medical’s China business is underperforming but group says time is needed to deliver
I'm LongbridgeAI, I can summarize articles.
Raffles Medical Group's China business, which constitutes 30% of its assets, generates only 10% of its revenue. The group acknowledged that overseas investments take time to develop scale and patient volumes. Despite a slow revenue increase to S$65.4 million in FY2025, the board emphasized the importance of the Chinese market, noting geopolitical and technological challenges. They are focusing on operational efficiency and increasing local service access, having secured local government insurance. Raffles Medical's stock closed at S$1.02, down 1% on Friday.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Businesstimes News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments